598 related articles for article (PubMed ID: 32659974)
1. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
Muller A; Vlahov D; Akiyama MJ; Kurth A
Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
[TBL] [Abstract][Full Text] [Related]
2. Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
Yeung A; Palmateer NE; Dillon JF; McDonald SA; Smith S; Barclay S; Hayes PC; Gunson RN; Templeton K; Goldberg DJ; Hickman M; Hutchinson SJ
J Hepatol; 2022 Mar; 76(3):549-557. PubMed ID: 34634387
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
[TBL] [Abstract][Full Text] [Related]
4. Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Heo M; Agyemang L; Norton BL; Hidalgo J; Lora K; Litwin AH
Clin Infect Dis; 2020 Jun; 70(12):2695-2702. PubMed ID: 31346609
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C reinfection in former and active injecting drug users in Belgium.
Busschots D; Bielen R; Koc ÖM; Heyens L; Verrando R; de Galocsy C; Van Steenkiste C; Nevens F; Midgard H; Dalgard O; Robaeys G
Harm Reduct J; 2021 Oct; 18(1):102. PubMed ID: 34641896
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
[TBL] [Abstract][Full Text] [Related]
7. Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies.
Sacks-Davis R; van Santen DK; Boyd A; Young J; Stewart A; Doyle JS; Rauch A; Mugglin C; Klein M; van der Valk M; Smit C; Jarrin I; Berenguer J; Lacombe K; Requena MB; Wittkop L; Leleux O; Bonnet F; Salmon D; Matthews GV; Guy R; Martin NK; Spelman T; Prins M; Stoove M; Hellard M;
Lancet HIV; 2024 Feb; 11(2):e106-e116. PubMed ID: 38224708
[TBL] [Abstract][Full Text] [Related]
8. Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta-analysis.
Munari SC; Traeger MW; Menon V; Latham NH; Manoharan L; Luhmann N; Baggaley R; MacDonald V; Verster A; Siegfried N; Conway B; Klein M; Bruneau J; Stoové MA; Hellard ME; Doyle JS
Liver Int; 2023 Dec; 43(12):2625-2644. PubMed ID: 37817387
[TBL] [Abstract][Full Text] [Related]
9. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
[TBL] [Abstract][Full Text] [Related]
10. Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Barnett T; Drost A; Gray-Schleihauf C; Guarasci K; Lundgren K; Milne R; Grebely J; Fraser C
Int J Drug Policy; 2021 Oct; 96():103418. PubMed ID: 34538704
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
[TBL] [Abstract][Full Text] [Related]
12. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era.
Ingiliz P; Wehmeyer MH; Boesecke C; Schulze Zur Wiesch J; Schewe K; Lutz T; Baumgarten A; Simon KG; Hueppe D; Rockstroh JK; Mauss S; Christensen S; ;
Clin Infect Dis; 2020 Aug; 71(5):1248-1254. PubMed ID: 31562816
[TBL] [Abstract][Full Text] [Related]
13. Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies.
Iversen J; Wand H; McManus H; Dore GJ; Maher L
Addiction; 2023 May; 118(5):901-911. PubMed ID: 36524842
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
Hajarizadeh B; Cunningham EB; Valerio H; Martinello M; Law M; Janjua NZ; Midgard H; Dalgard O; Dillon J; Hickman M; Bruneau J; Dore GJ; Grebely J
J Hepatol; 2020 Apr; 72(4):643-657. PubMed ID: 31785345
[TBL] [Abstract][Full Text] [Related]
15. Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago.
Tatara E; Gutfraind A; Collier NT; Echevarria D; Cotler SJ; Major ME; Ozik J; Dahari H; Boodram B
PLoS One; 2022; 17(3):e0264983. PubMed ID: 35271634
[TBL] [Abstract][Full Text] [Related]
16. Incidence of HIV and hepatitis C virus among people who inject drugs, and associations with age and sex or gender: a global systematic review and meta-analysis.
Artenie A; Stone J; Fraser H; Stewart D; Arum C; Lim AG; McNaughton AL; Trickey A; Ward Z; Abramovitz D; Alary M; Astemborski J; Bruneau J; Clipman SJ; Coffin CS; Croxford S; DeBeck K; Emanuel E; Hayashi K; Hermez JG; Low-Beer D; Luhmann N; Macphail G; Maher L; Palmateer NE; Patel EU; Sacks-Davis R; Van Den Boom W; van Santen DK; Walker JG; Hickman M; Vickerman P;
Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):533-552. PubMed ID: 36996853
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
[TBL] [Abstract][Full Text] [Related]
18. Direct-acting antiviral treatment for hepatitis C, reinfection and mortality among people attending an inner-city community health centre in Victoria, Canada.
Selfridge M; Cunningham EB; Milne R; Drost A; Barnett T; Lundgren K; Guarasci K; Grebely J; Fraser C
Int J Drug Policy; 2019 Oct; 72():106-113. PubMed ID: 31178254
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
[TBL] [Abstract][Full Text] [Related]
20. Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.
Cunningham EB; Applegate TL; Lloyd AR; Dore GJ; Grebely J
Nat Rev Gastroenterol Hepatol; 2015 Apr; 12(4):218-30. PubMed ID: 25782091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
